Synergistic anti-leukemic activity of imatinib in combination with a small molecule Grb2 SH2 domain binding antagonist

Leukemia. 2014 Apr;28(4):948-51. doi: 10.1038/leu.2013.323. Epub 2013 Oct 31.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Intramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Aldehyde Dehydrogenase / metabolism
  • Antineoplastic Agents / pharmacology*
  • Benzamides / administration & dosage
  • Benzamides / pharmacology*
  • Drug Synergism
  • GRB2 Adaptor Protein / antagonists & inhibitors*
  • GRB2 Adaptor Protein / chemistry
  • GRB2 Adaptor Protein / metabolism
  • Humans
  • Imatinib Mesylate
  • K562 Cells
  • Leukemia / drug therapy*
  • MicroRNAs / physiology
  • Piperazines / administration & dosage
  • Piperazines / pharmacology*
  • Protein Kinase Inhibitors / pharmacology*
  • Pyrimidines / administration & dosage
  • Pyrimidines / pharmacology*
  • src Homology Domains

Substances

  • Antineoplastic Agents
  • Benzamides
  • GRB2 Adaptor Protein
  • GRB2 protein, human
  • MicroRNAs
  • Piperazines
  • Protein Kinase Inhibitors
  • Pyrimidines
  • Imatinib Mesylate
  • Aldehyde Dehydrogenase